Results 141 to 150 of about 7,222 (160)

CoronaVac efficacy data from Turkey [PDF]

Lancet, The, 2021
Benjamin J Cowling
exaly   +3 more sources

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

MBio, 2022
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after two doses of CoronaVac; these levels were ...
Nicolas M S Galvez, Gaspar A Pacheco, Jorge A Soto   +2 more
exaly   +2 more sources

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group [PDF]

Frontiers in Immunology, 2022
CoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule.
Felipe E Reyes-Lopez, Mónica L Acevedo, Fernando Valiente-Echeverría   +2 more
exaly   +2 more sources

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster

Antibodies, 2022
Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose.
Chin Shern Lau, Jianxin Huo, Tar Choon Aw   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Safety and Immunogenicity of CoronaVac in People Living with HIV

SSRN Electronic Journal, 2021
Background: People living with HIV (PLWH) may have a poor or delayed response to vaccines, mainly when CD4+ T cell counts are low. There are limited data concerning the safety and immunogenicity of COVID-19 vaccines in PLWH. Methods: This prospective controlled study evaluated the safety and immunogenicity of the SARS-CoV-2 inactivated vaccine ...
Lucas Chaves Netto, Karim Yaqub Ibrahim, Camila Melo Picone, Ana Paula Pereira da Silva Alves, Eliane Vieira Aniceto, Mariana Rodrigues Santiago, Patrícia da Silva Spindola Parmejani, Nádia Emi Aikawa, Ana Cristina Medeiros-Ribeiro, Sandra Gofinet Pasoto, Emily Figueiredo Neves Yuki, Carla G. S. Saad, Tatiana Pedrosa, Amanda Nazareth Lara, Carina Ceneviva, Eloisa Silva Dutra de Oliveira Bonfa, Esper Georges Kallas, Vivian Iida Avelino-Silva   +17 more
openaire   +1 more source

Alopecia areata after CoronaVac vaccination

Journal of Cosmetic Dermatology, 2022
Miguel Aristizabal, Jeffery T. S. Hsu, Michael H. Gold   +2 more
openaire   +2 more sources

CoronaVac Progress Update

2020
Syafiq, Ahmad, Bahrian, Juan Dennis
openaire   +1 more source

Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines

Inflammopharmacology, 2022
Sevilay Batibay, Rezan Kocak Ulucaköy, Feride Gogus   +2 more
exaly  

Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study

Emerging Microbes and Infections, 2022
Eric Yuk Fai Wan, Xuxiao Ye, Anna Hoi Ying Mok   +2 more
exaly  

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study

The Lancet Regional Health Americas, 2022
Thiago Cerqueira-Silva, Vinicius DE ARAÚJO OLIVEIRA, Viviane Boaventura   +2 more
exaly